RxDoctor Payments Data

Biljana Kostic, MD

Internal Medicine · Bermuda Dunes, CANPI 1184703621

Payments from drug & device makers

$345in general payments, 2019–2025

Across 32 payments — averaging $10.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$175
  • Novo Nordisk$86
  • Pfizer$26
  • Sunovion Pharmaceuticals Inc.$24
  • GSK$21
  • AbbVie$12

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$345 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$56,085
Medicare patients
194
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin217$300,701
EliquisApixaban187$224,466
OzempicSemaglutide83$94,904
XareltoRivaroxaban67$88,308
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$26,630
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$23,192
Soliqua 100-33Insulin Glargine/Lixisenatide15$23,161
JanuviaSitagliptin Phosphate14$20,607
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$18,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$15,719
Levothyroxine Sodium941$11,867
Breo ElliptaFluticasone/Vilanterol24$10,831
Atorvastatin Calcium1,056$9,754
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$8,622
AmbienZolpidem Tartrate12$7,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$224,466187 claims
Novo NordiskOzempic$86$94,90483 claims
Johnson & JohnsonXarelto$175$88,30867 claims
GSKBreo Ellipta$21$10,83124 claims
AbbVieSynthroid$12$3,30176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bermuda Dunes

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →